Characteristics and Survival of Patients with Primary and Secondary Distant Metastasis of Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BACKGROUND: Approximately 20% of patients with oropharyngeal squamous cell carcinoma (OPSCC) develop distant metastases (DM). Survival outcomes after DM vary widely depending on clinical and biologic factors. This study compared baseline characteristics, management strategies, and oncologic outcomes among OPSCC patients with primary and secondary DM to better inform prognostication and therapeutic planning. METHODS: We conducted a retrospective cohort study of patients treated at a tertiary care center with HPV/p16-positive, HPV/p16-negative, or unknown-status OPSCC who developed DM at any point. Treatments included surgery, radiation, and systemic therapy delivered with curative or non-curative intent. Cohort characteristics and overall survival (OS), stratified by primary versus secondary DM and treatment subgroups, were assessed using chi-square tests and Kaplan Meier analyses. RESULTS: A total of 132 patients were included: 18 with primary DM and 114 with secondary DM. HPV-positivity was lower in primary versus secondary DM group (22.2% vs 75.4%). Median follow-up was 32.4 months. Median OS from DM diagnosis was significantly shorter for primary versus secondary DM (9.6 vs 20.4 months; HR 2.00, 95% CI 1.16-3.46). Patients with secondary DM were more likely to receive metastasis-directed therapy (MDT). Median OS was 56.4 months with MDT and 13.2 months without (HR 0.38, 95% CI 0.23-0.61). CONCLUSIONS: This is the largest single center analysis of DM OPSCC to date. Primary DM OPSCC was associated with worse survival and lower HPV-positivity. Patients with DM, particularly those with HPV-positive disease, may achieve extended survival following aggressive treatment such as MDT.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2026-11-18
DOI
https://doi.org/10.1093/oncolo/oyag449
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Characteristics and Survival of Patients with Primary and Secondary Distant Metastasis of Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Linda X. Yin, Eric J. Moore, Casey Fazer-Posorske, Jamie J. O’Byrne et al.
The Oncologist
Head and Neck Cancer Studies
article

Characteristics and Survival of Patients with Primary and Secondary Distant Metastasis of Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Linda X. Yin, Eric J. Moore, Casey Fazer-Posorske, Jamie J. O’Byrne, Kathryn Mary Abel, Katharine Andress Rowe Price, David M. Routman, Michelle Neben Wittich, Jessica M. Wilson, Harry E. Fuentes Bayne, Kendall K. Tasche, Patrick Walsh McGarrah, Chadi Nimeh Abdel‐Halim, Scott C. Lester, Daniel L. Price, Ruth Agwaze, Daniel J Ma
article en

Abstract

BACKGROUND: Approximately 20% of patients with oropharyngeal squamous cell carcinoma (OPSCC) develop distant metastases (DM). Survival outcomes after DM vary widely depending on clinical and biologic factors. This study compared baseline characteristics, management strategies, and oncologic outcomes among OPSCC patients with primary and secondary DM to better inform prognostication and therapeutic planning. METHODS: We conducted a retrospective cohort study of patients treated at a tertiary care center with HPV/p16-positive, HPV/p16-negative, or unknown-status OPSCC who developed DM at any point. Treatments included surgery, radiation, and systemic therapy delivered with curative or non-curative intent. Cohort characteristics and overall survival (OS), stratified by primary versus secondary DM and treatment subgroups, were assessed using chi-square tests and Kaplan Meier analyses. RESULTS: A total of 132 patients were included: 18 with primary DM and 114 with secondary DM. HPV-positivity was lower in primary versus secondary DM group (22.2% vs 75.4%). Median follow-up was 32.4 months. Median OS from DM diagnosis was significantly shorter for primary versus secondary DM (9.6 vs 20.4 months; HR 2.00, 95% CI 1.16-3.46). Patients with secondary DM were more likely to receive metastasis-directed therapy (MDT). Median OS was 56.4 months with MDT and 13.2 months without (HR 0.38, 95% CI 0.23-0.61). CONCLUSIONS: This is the largest single center analysis of DM OPSCC to date. Primary DM OPSCC was associated with worse survival and lower HPV-positivity. Patients with DM, particularly those with HPV-positive disease, may achieve extended survival following aggressive treatment such as MDT.

The Oncologist
Mayo Clinic (US), Odense University Hospital (DK), University of Rochester Medical Center (US), Mayo Clinic in Arizona (US), Mayo Clinic Comprehensive Cancer Center (Minnesota) (US), University of Rochester (US)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon